EBP, or Emopamil Binding Protein, activators comprise a select group of chemical compounds that function to specifically enhance the activity of EBP, a protein encoded by the EBP gene. EBP is an essential component of the mevalonate pathway, a critical metabolic route responsible for the synthesis of sterols, including cholesterol. Activators of EBP typically work by engaging with the protein at a molecular level to stabilize its active form or to enhance its interaction with substrates or cofactors required for its enzymatic activity. These compounds can include small molecules that bind to the active site of EBP, altering its conformation in a way that promotes its activity. Some EBP activators may also function by binding to allosteric sites, which are distinct from the enzyme's active site, resulting in a conformational change that increases the protein's catalytic efficiency. By influencing EBP's activity, these activators play a significant role in modulating the mevalonate pathway and, consequently, the biosynthesis of various sterols and isoprenoids.
The biochemical activation mechanisms by which EBP activators exert their effects are highly specific and tailored to the structure and function of the EBP enzyme. These activators may enhance the binding affinity of EBP for its substrates, thereby increasing the rate of reaction it catalyzes. Others might act by protecting EBP from degradative processes, ensuring a more stable and prolonged activity within the cellular environment. Some activators are designed to mimic the natural substrates of EBP, thereby providing a more efficient pathway for the enzyme to catalyze its intended reaction. By directly affecting the enzymatic action of EBP, activators ensure that the rate of sterol synthesis is maintained at a level conducive to the needs of the cell. The precise activity of each activator is a result of careful molecular design that takes into account the three-dimensional structure of EBP, ensuring that the activation is as effective as possible without altering other cellular functions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $27.00 $2809.00 $129.00 $210.00 $583.00 $88.00 | 11 | |
Cholesterol is a direct substrate for EBP, which is a δ(8)-δ(7) sterol isomerase in the cholesterol biosynthesis pathway. The binding and conversion of cholesterol by EBP enhance its enzymatic activity. | ||||||
25-Hydroxycholesterol | 2140-46-7 | sc-214091B sc-214091 sc-214091A sc-214091C | 5 mg 10 mg 25 mg 100 mg | $53.00 $91.00 $169.00 $474.00 | 8 | |
25-Hydroxycholesterol serves as a ligand for LXRs affecting SREBP processing and indirectly influencing EBP by modulating cholesterol levels and metabolism. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin is an HMG-CoA reductase inhibitor that can lead to compensatory upregulation of the cholesterol biosynthesis pathway, thereby potentially enhancing the functional activity of EBP. | ||||||
Geranylgeraniol | 24034-73-9 | sc-200858 sc-200858A | 20 mg 100 mg | $162.00 $474.00 | 14 | |
Geranylgeraniol can upregulate the mevalonate pathway, which is upstream of cholesterol synthesis, potentially increasing the availability of substrates for EBP. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
As with simvastatin, lovastatin is an HMG-CoA reductase inhibitor that can indirectly enhance the activity of EBP through feedback mechanisms in cholesterol biosynthesis. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin is another HMG-CoA reductase inhibitor that, through feedback mechanisms, may increase the flow of substrates through the cholesterol biosynthesis pathway, thus enhancing EBP activity. | ||||||
Farnesol | 4602-84-0 | sc-204748 sc-204748A | 50 ml 100 ml | $281.00 $374.00 | 2 | |
As an intermediate in the mevalonate pathway, farnesol can upregulate the synthesis of cholesterol precursors, indirectly enhancing the enzymatic activity of EBP. | ||||||
Squalene | 111-02-4 | sc-281155 sc-281155A sc-281155B | 10 ml 100 ml 500 ml | $49.00 $92.00 $215.00 | 1 | |
As a precursor in the cholesterol biosynthesis pathway, squalene's presence may indirectly signal for the enhanced activity of downstream enzymes like EBP. | ||||||
Lanosterol | 79-63-0 | sc-215229 sc-215229A | 1 mg 5 mg | $105.00 $350.00 | 2 | |
Lanosterol is metabolized by EBP in the cholesterol biosynthesis pathway. Its conversion to more downstream sterols is facilitated by EBP, enhancing its enzymatic function. | ||||||